Company intelligence / Profile preview

Selva Therapeutics

San Diego, California, United Statesselvarx.com ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Developing SLV213 oral antiviral showing broad-spectrum activity against multiple viruses. Completed Phase I safety trial successfully with no dose-limiting toxicities. Demonstrated preclinical synergy with direct-acting antivirals and protective effect against COVID-19 lung damage.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

SLV213

1 more asset in the full pipeline.

Partnerships

California Innovation Fund (investor & strategic partner)Undisclosed collaborators for clinical trials

Beyond the preview

Go deeper on Selva Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selva Therapeutics.